On the Calculation of Time Alignment Errors in Data Management Platforms for Distribution Grid Data.

Sensors (Basel)

Department of Computer Science and Engineering, University of Connecticut, Storrs, CT 06269, USA.

Published: October 2021

The operation and planning of distribution grids require the joint processing of measurements from different grid locations. Since measurement devices in low- and medium-voltage grids lack precise clock synchronization, it is important for data management platforms of distribution system operators to be able to account for the impact of nonideal clocks on measurement data. This paper formally introduces a metric termed Additive Alignment Error to capture the impact of misaligned averaging intervals of electrical measurements. A trace-driven approach for retrieval of this metric would be computationally costly for measurement devices, and therefore, it requires an online estimation procedure in the data collection platform. To overcome the need of transmission of high-resolution measurement data, this paper proposes and assesses an extension of a Markov-modulated process to model electrical traces, from which a closed-form matrix analytic formula for the Additive Alignment Error is derived. A trace-driven assessment confirms the accuracy of the model-based approach. In addition, the paper describes practical settings where the model can be utilized in data management platforms with significant reductions in computational demands on measurement devices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539573PMC
http://dx.doi.org/10.3390/s21206903DOI Listing

Publication Analysis

Top Keywords

data management
12
management platforms
12
measurement devices
12
platforms distribution
8
measurement data
8
data paper
8
additive alignment
8
alignment error
8
data
7
measurement
5

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Background: The present study recapitulates the potency of the novel synthesized piperazine-benzoquinone derivative as a lead molecule selectively targeting AChE along with the antioxidative potential for the management of cognitive decline in Alzheimer's disease.

Method: Novel piperazine-benzoquinone derivative was synthesized implementing appropriate synthetic procedures and was characterized by various spectral and elemental techniques. The purity of this synthetic analogue was ascertained by TLC, melting point determination and elemental analyses.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path institute, Tucson, AZ, USA.

Background: To help improve the Alzheimer's disease (AD) therapeutics research and development process, the Critical Path for Alzheimer's Disease (CPAD) Consortium at the Critical Path Institute (C-Path) provides a neutral framework for the drug development industry, regulatory agencies, academia, and patient advocacy organizations to collaborate. CPAD's extensive track record of developing regulatory-grade quantitative drug development tools motivates sponsors to share patient-level data and neuroimages from clinical trials. CPAD leverages these data and uses C-Path's core competencies in data management and standardization, quantitative modeling, and regulatory science to develop tools that help de-risk decision making in AD drug development.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Real-World data platforms for Alzheimer's Disease (AD) offer a unique opportunity to improve health equity through better understanding of health disparities and inclusivity in research, which is critical to translatability of research findings. AD research in the US and globally remains largely inaccessible to many individuals due to individual-level, study-level, investigator-level and larger systemic barriers. ALZ-NET, a US-based registry to evaluate longitudinal outcomes of patients being evaluated for or treated with novel FDA-approved AD therapy, and New IDEAS, an observational US-based longitudinal study of amyloid PET clinical utility, both offer opportunities for examining care, inclusivity, and disparities.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Pentara Corporation, Salt Lake City, UT, USA.

Background: Alzheimer's disease (AD) presents unique challenges in clinical trials involving small molecules. Multifaceted issues plague such trials, emphasizing susceptibility to fraud from clinical sites and "professional patients". The relative ease of simulating Alzheimer's diagnosis, coupled with inadequate oversight by Contract Research Organizations (CROs), creates fertile ground for deceptive practices.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!